Three-Month Marketing Exclusivity Proposed For UK First-In-Class Switches
This article was originally published in The Tan Sheet
Executive Summary
A drug sponsor that is the first to successfully switch an ingredient from Rx to nonprescription status in the UK would receive 90 days of marketing exclusivity under a Medicines Control Agency proposal